Coherus Oncology Inc (CHRS)

EBITDA Margin

-210.82%

Quarterly · Period ending:

CHRS logo

CHRS EBITDA Margin

Latest reported-210.82%
CHRS Quarterly EBITDA Margin (-1846.44% → -210.82%)
High-resolution chart · PNG

CHRS ebitda margin history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Coherus Oncology Inc EBITDA Margin — Quarterly
Period endingEBITDA Margin
-210.8199%
-275.1259%
-338.8924%
-356.2873%
-405.393%
-581.6818%
-81.8503%
-5.4257%
-9.8493%
-2,747.4437%
-74.2658%
-38.6949%
-54.578%
-200.6043%
-106.7979%
-171.9686%
-70.9598%
-143.638%
-52.4826%
-38.6228%
-26.5577%
-200.4601%
15.6413%
30.352%
49.0005%
35.7574%
37.7931%
47.6326%
33.76%
-40.6949%
0%
0%
0%
0%
0%
0%
-3,740.5018%
-44,460.2484%
-8,622.9858%
53.4388%
-445.9483%
-514.8879%
-502.2946%
-988.0843%
-853.9761%
-698.9157%
-384.8914%
-48.0999%
-478.9728%
-620.495%
-907.6299%
-3,830.0395%
-1,811.6371%
-1,846.4427%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.